13 research outputs found
Uloga ultrazvuÄne elastografije u dijagnostici patoloÅ”kih stanja testisa i skrotuma
Several years ago, elastography emerged as a potentially very useful ultrasound
technique that is currently used in diagnostic workup of the breast, liver and some other organ systems,
whereas for other ones it is still mainly in the phase of research. The aim of the study was to compare
elasticity index (EI) of testicles using strain elastography in healthy subjects and those with pathologic
changes of testicles/scrotum. A total of 117 patients were included in the study. Measurements
were performed on a Logiq E9 ultrasound system using strain elastography. In healthy subjects, the
mean EI value was 1.34Ā±0.35 for right testis and 1.49Ā±0.47 for left testis. Increased mean EI values
were found in the following six conditions: patients with varicocele, infertile patients, solitary testis
after orchidectomy of the other testicle because of tumor, patients with testicular tumors, patients after
orchidopexy of undescended testicle, and patients with congenitally smaller testicle. There is a paucity
of literature data on the use of elastography in testes, as well as on normal elastography values in testicular
tissue. Strain elastography was demonstrated to be a valuable method to acquire additional
information in patients with pathologic changes in testicles/scrotum. These data provide reference
values for further research in a larger sample of subjects.Prije nekoliko godina pojavila se elastografija kao potencijalno vrlo korisna ultrazvuÄna metoda koja je danas u svakodnevnoj
upotrebi u dijagnostici dojke, jetre i drugih organskih sustava, dok je za druge organe joŔ u fazi istraživanja i evaluacije.
Cilj istraživanja bio je usporediti indeks elastiÄnosti (EI) testisa u zdravih ispitanika i bolesnika s patoloÅ”kim promjenama
testisa i skrotuma. Istraživanje je provedeno kod ukupno 117 ispitanika od kojih je bilo 40 zdravih i 77 ispitanika s
patoloÅ”kim promjenama testisa i skrotuma. Mjerenja su provedena na ultrazvuÄnom aparatu Logiq E9 primjenom programa
za sonoelastografska mjerenja. Kod zdravih ispitanika vrijednosti EI bile su 1,34Ā±0,35 za desni testis i 1,49Ā±0,47 za lijevi
testis. Prema vrijednosti EI, pojaÄana tvrdoÄa tkiva testisa uoÄena je kod sljedeÄih stanja: varikokele, neplodnosti, ostatnog
testisa kod stanja nakon orhidektomije drugog testisa, tumora testisa, stanja nakon orhidopeksije nespuŔtenog testisa i kongenitalno
manjeg testisa. Malo je podataka u literaturi o elastografiji testisa, kao i o normalnim elastografskim vrijednostima
tkiva testisa. Elastografija testisa se u naÅ”em ispitivanju pokazala korisnom metodom za dobivanje dodatnih dijagnostiÄkih
informacija kod bolesnika s patoloÅ”kim promjenama testisa i skrotuma, no potrebna su daljnja istraživanja s veÄim skupinama
bolesnika
OVERVIEW OF SYMPTOMS OF ONGOING SYMPTOMATIC AND POST-COVID-19 PATIENTS WHO WERE REFFERED TO PULMONARY REHABILITATION - FIRST SINGLE-CENTRE EXPERIENCE IN CROATIA
Background: Coronavirus-2 pandemic has changed the functioning of health systems worldwide. It is not yet fully known which
symptoms of the disease are most commonly presented in patients referred for pulmonary rehabilitation. Our aim was to investigate
the profile of patients referred for pulmonary rehabilitation; what symptoms they had during the acute phase of the disease and what
symptoms were still present at the start of pulmonary rehabilitation.
Subjects and methods: Study included ongoing symptomatic and post-COVID patients who attended standard, in person
pulmonary rehabilitation program. Patients had COVID-19 disease at least four weeks before attending pulmonary rehabilitation.
Patients completed questionnaires of self-reported somatic deficits during acute and post-COVID-19 stage as well as questionnaires
regarding their psychological symptoms. Pulmonary function test, expiratory and inspiratory muscle strenght, hand grip strenght
and six-minute walk test was performed prior and after pulmonary rehabilitation.
Results: Study included 63 patients (32 male, 31 female), with mean age of 52.9 years. During acute COVID-19, majority of
patients complained of fatigue, cough, dyspnea, myalgia and headache. More than 85% of patients reported pulmonary deficits
during ongoing symptomatic and post-COVID-19 stage. Emotional distress and anxiety levels were significantly elevated in acute
stage, while depression, anger and the need for help was not significantly elevated. All reported symptoms were significantly reduced
in post-COVID-19 stage. There was statistically significant difference in six-minute walk distance, inspiratory and expiratory muscle
strenght and hand grip strenght between first and final testing.
Conclusions: Results of our study are similar with previous studies, the most common symptoms during acute phase were fatigue,
cough and dyspnea and fatigue and respiratory problems during ongoing symptomatic and post-COVID stage. Emotional distress
diminishes signifiacantly in post-COVID stage. Further larger studies are needed to clarify which acute disease symptoms are
predominant in patients referred to pulmonary rehabilitation and cause prolongued discomfort
Imunoterapija u tretmanu ne-sitnostaniÄnog raka pluÄa
Lung cancer is leading cause of death among malignant disease Worldwide and it is responsible for more than 1, 5 million deaths each year. Lung cancer is divided in two major groups: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Despite significant improvements, for vast majority of patients chemotherapy still remains the treatment of choice in the first line setting. Progress over the last decade has led to the recognition of immunoevasion as of the leading hallmarks of cancer development. Clinical development was focused on immune checkpoint inhibitors, cytotoxic T-lymphocyteāassociated antigen 4 (CTLA4) and programmed death (PD1/PD-L1) pathway. Programmed death 1 protein is another T-cell coinhibitory receptor with a structure similar to that of CTLA-4 but with a distinct biologic function and ligand specificity and it is stimulated with PD-L1. PD-1 or PD-L1 blockade with drugs like nivolumab, pembrolizumab or atezolizumab resulted in superior efficacy comparing to standard chemotherapy in first-line setting. In patient with high PD-L1 expression (50% or more) pemborlizumab should be treatment of choice in first-line setting. PD-L1 expression is at the moment only available biomarker who can predict response to immune checkpoint inhibitors.Karcinom pluÄa vodeÄi je uzrok smrti od malignih bolesti te je odgovoran za viÅ”e od 1,5 milijuna smrti. U veÄine bolesnika osnovu lijeÄenja karcinoma pluÄa Äini kemoterapija temeljena na platini. Unazad desetak godina, brojna se istraživanje provode o ulozi imunoloÅ”kog sutava u karcinogenezi. Tumori uspjevaju izbjeÄi nadzor imunoloÅ”kog sustava te tako rasti i metastazirati. Koncpet aktivacije imunoloÅ”kog sutava iznimno je zanimljiv te se pokazalo da blokatori kontrolnih toÄaka pokazauju dobro uÄinkovitost u lijeÄenju solidnih tumora poput melanoma ili bubrega. U zadnjih pet godina, inhibitori kontrolnih toÄaka nivolumab, pembrolizumab i atezoilizumab pokazali su se kao iznimno uÄinkoviti lijekovi u lijeÄenju bolesnika s karcinomom pluÄa ranije lijeÄenih klasiÄnom kemoterapijom. Pembrolizumab se takoÄer pokazao kao iznimno uÄinkovit u lijeÄenju bolesnika sa visokom PD-L1 ekspresijom (PD-L1ā„50%) u prvoj liniji lijeÄenja. Ono Å”to je nužno je pronaÄi biomarker koji bi ukazivao koji Äe bolesnici regirati na lijeÄenje imunoterapijom. Danas znamo da Å”to je viÅ”a ekspresija PD-L1 bolji je odgovor na imunoterapiju, ali i negativni bolesnici mogu odgovoriti na lijeÄenje. Imunoterapija inhibitorima kontrolnih toÄaka danas je standard u drugoj liniji lijeÄenja karcinoma pluÄa malih stanica, te je pembrolizumab najbolja opcija za lijeÄenje visoko pozitivnih PD-L1 bolesnika u prvoj liniji lijeÄenja
Risk factors and severity of functional impairment in long COVID: a single-center experience in Croatia
Aim To determine the frequency of common symptoms
in long COVID and their effect on the quality of life, and to
determine the factors contributing to a more severe long
COVID.
Methods The study enrolled 266 patients who were either referred to long-COVID outpatient clinic or were inpatients undergoing rehabilitation. The data were collected
between December 2020 and May 2021. We evaluated the
symptoms experienced during acute and long COVID and
comorbidities. Functional status was assessed with Post
Covid Functional Status (PCFS).
Results The final sample consisted of 261 patients. After
acute COVID-19 period (>4 weeks), almost 80% of patients
had impaired functional status. Only 21.5% reported no
functional impairment (0 on PCFS scale). A higher PCFS
score was associated with female sex (P<0.001) and oxygen therapy requirement during acute disease (P=0.001).
However, it was not associated with having a pre-existing
lung disease (P=0.749). Disease severity did not pose a risk
for developing a more severe long COVID.
Conclusion Women were at greater risk for developing
greater functional impairment in long COVID, although we
have no explanation why. Malignant disease and hypertension also presented a risk factor for greater functional
impairment. More studies are warranted to determine if
patients with certain lung disease are more susceptible to
long COVID
RadioloÅ”ke dijagnostiÄke metode kod transplantacije bubrega
Radiological diagnostic methods have a significant role in the preoperative and postoperative care of patients after kidney transplantation. Improvement and innovations in technology, but also the growing experience of the radiologists who deal with kidney transplant patients as part of the transplant team lead to earlier detection of complications in the postoperative period, which are the leading cause of transplant failure. In this article, we describe, through diagnostic imaging examples, detailed evaluation of all possible complications that can occur after kidney transplantation, with evaluation of different possible diagnostic methods that can be used in the preoperative assessment and postoperative follow up and care of the transplanted patient. The goal of this article is to demonstrate and summarize in detail the possible complications of renal transplantation and how to best diagnostically approach them, with special reference to ultrasound which is the main imaging method for this group of conditions.RadioloÅ”ke dijagnostiÄke metode imaju znaÄajnu ulogu u prijeoperacijskom i poslijeoperacijskom razdoblju kod bolesnika s transplantiranim bubregom. Sve bolje tehnoloÅ”ke moguÄnosti i inovacije, ali i sve veÄe iskustvo radiologa koji se kao sastavni dio transplantacijskog tima bave transplantiranim bolesnicima dovode do ranog prepoznavnja poslijetransplantacijskih komplikacija, najznaÄajnijeg uzroka propadanja transplantiranog organa. U ovom Älanku predstavljamo kroz primjere detaljan prikaz svih moguÄih komplikacija te analizu moguÄnosti razliÄitih dijagnostiÄkih metoda koje se primjenjuju u pripremi za transplantaciju i poslijetransplantacijskoj obradi i praÄenju transplantiranog bolesnika. Cilj ovoga Älanka je detaljno prikazati i sistematizirati moguÄe komplikacije te kako im dijagnostiÄki pristupiti, s naglaskom na ultrazvuk koji ima glavnu ulogu u dijagnostici ovih stanja
Multimodality Imaging of Cardiac Myxomas
Cardiac myxomas are the most common benign cardiac neoplasms. Echocardiography is the first-line imaging modality used to analyze cardiac masses, allowing the detection of tumor location, size, and mobility. However, additional imaging techniques are required to confirm the diagnosis, evaluate tissue characteristics of the mass, and assess potential invasion of surrounding structures. Second-line imaging includes cardiac magnetic resonance imaging (MRI) and/or computed tomography (CT) depending on availability and the patientās characteristics and preferences. The advantages of CT include its wide availability and fast scanning, which allows good image quality even in patients who have difficulty cooperating. MRI has excellent soft-tissue resolution and is the gold standard technique for noninvasive tissue characterization. In some cases, evaluation of the tumor metabolism using 18F-fluorodeoxyglucose positron emission tomography with CT may be useful, mainly if the differential diagnosis includes primary or metastatic cardiac malignancies. A cardiac myxoma can be identified by its characteristic location within the atria, typically in the left atrium attached to the interatrial septum. The main differential diagnoses include physiological structures in the atria like crista terminalis in the right atrium and the coumadin ridge in the left atrium, intracardiac thrombi, as well as other benign and malignant cardiac tumors. In this review paper, we describe the characteristics of cardiac myxomas identified using multimodality imaging and provide tips on how to differentiate myxomas from other cardiac masses